Cogent Biosciences (Cogent Biosciences) Cash Flow from Financing : $377.15 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cogent Biosciences Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Cogent Biosciences received $213.70 Mil more from issuing new shares than it paid to buy back shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.36 Mil on other financial activities. In all, Cogent Biosciences earned $214.06 Mil on financial activities for the three months ended in Mar. 2024.

Cogent Biosciences Cash Flow from Financing Historical Data

The historical data trend for Cogent Biosciences's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cogent Biosciences Cash Flow from Financing Chart

Cogent Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

Get a 7-Day Free Trial

0.11

232.20

37.98

163.56

163.54

Cogent Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash Flow from Financing	Get a 7-Day Free Trial															0.45	162.09	1.00	-	214.06

Cogent Biosciences Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Cogent Biosciences's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	161.819	+	0	+	0	+	0	+	0	+	1.717
=	163.54

Cogent Biosciences's Cash from Financing for the quarter that ended in Mar. 2024 is:

	Cash Flow from Financing		(Q: Mar. 2024 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	213.701	+	0	+	0	+	0	+	0	+	0.356
=	214.06

Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $377.15 Mil.

Cogent Biosciences (NAS:COGT) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Cogent Biosciences's issuance of stock for the three months ended in Mar. 2024 was $213.70 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Cogent Biosciences's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Cogent Biosciences's net issuance of debt for the three months ended in Mar. 2024 was $0.00 Mil. Cogent Biosciences received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Cogent Biosciences's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. Cogent Biosciences paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cogent Biosciences's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. Cogent Biosciences received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Cogent Biosciences's other financing for the three months ended in Mar. 2024 was $0.36 Mil. Cogent Biosciences received $0.36 Mil on other financial activities.

Cogent Biosciences Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Cogent Biosciences's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Cogent Biosciences (Cogent Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cogent Biosciences Inc (NAS:COGT) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451

Website

https://www.cogentbio.com

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

Executives

Fairmount Funds Management Llc	10 percent owner, other: See Remarks	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Evan Kearns	officer: Chief Legal Officer	AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
John L. Green	officer: Chief Financial Officer	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
John Edward Robinson	officer: Chief Scientific Officer	C/O COGENT BIOSCIENCES, INC., 200 CAMBRIDGE PARK DRIVE, SUITE 2500, CAMBRIDGE MA 02140
Christopher W. Cain	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Peter Evan Harwin	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Arlene Morris	director	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Todd Shegog	director	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Jessica Sachs	officer: Chief Medical Officer	C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Matthew Ros	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Karen Jean Ferrante	director	150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Andrew R Robbins	director, officer: President and CEO	C/O 3200 WALNUT ST, BOULDER CO 80301
Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Vhcp Management Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Ii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018